MarketCap
Facebook
X
TelegramQuartalsbericht 2023-Q3
hinzugefügt 06.06.2026
Adamis Pharmaceuticals Corporation Operativer Cashflow 2011-2026 | ADMP
Operativer Cashflow Jährlich Adamis Pharmaceuticals Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -25.9 M | -37.8 M | -20.9 M | -19.9 M | -32.7 M | -15.1 M | -21.2 M | - | -6.78 M | -2.56 M | -3.35 M | -4.31 M | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -2.56 M | -37.8 M | -17.3 M |
Operativer Cashflow Vierteljährlich Adamis Pharmaceuticals Corporation
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.85 M | -4.12 M | -1.55 M | - | -24.4 M | -16.9 M | -6.99 M | - | -31.1 M | -21.3 M | -4.54 M | - | -15.5 M | -9.38 M | -4.24 M | - | -16.9 M | -12.7 M | -8.27 M | - | -20.4 M | -12.4 M | -7.95 M | - | -9.89 M | -6.98 M | -3.51 M | - | -17.9 M | - | - | - | - | - | - | - | - | -3.9 M | -2.66 M | - | -4.44 M | -1.98 M | -1.68 M | - | -2.54 M | -1.93 M | -1.22 M | - | -2.7 M | -1.99 M | -1.2 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -1.2 M | -31.1 M | -8.82 M |
Operativer Cashflow anderer Aktien in der Arzneimittelhersteller
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Endo International plc
ENDP
|
435 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-5.46 M | - | - | $ 36.6 M |  USA |
 |
Cumberland Pharmaceuticals
CPIX
|
4.93 M | $ 5.59 | -0.27 % | $ 83 M | USA |
 |
HEXO Corp.
HEXO
|
-117 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-435 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
-11.4 M | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
-19.1 M | - | - | $ 50.1 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-99.2 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-9.58 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
-14.3 M | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
25.9 M | $ 2.62 | -2.24 % | $ 1 B | Canada |
 |
Athenex
ATNX
|
-131 M | - | -23.39 % | $ 1.76 M | USA |
 |
Harrow Health
HROW
|
43.9 M | $ 38.91 | 3.37 % | $ 1.43 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-46.9 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
268 M | - | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
50.7 M | - | -39.89 % | $ 27.7 M | USA |
 |
Organogenesis Holdings
ORGO
|
-10.3 M | $ 2.38 | 1.92 % | $ 302 M | USA |
 |
Canopy Growth Corporation
CGC
|
-166 M | $ 0.97 | -2.64 % | $ 104 M | Canada |
 |
Pacira BioSciences
PCRX
|
189 M | $ 22.87 | -0.52 % | $ 1.06 B | USA |
 |
Aurora Cannabis
ACB
|
16 M | $ 3.02 | -0.63 % | $ 166 M | Canada |
 |
Solid Biosciences
SLDB
|
-156 M | $ 7.18 | 0.56 % | $ 628 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-88 K | $ 1.13 | 3.21 % | $ 1.4 M | USA |
 |
Jupiter Wellness
JUPW
|
-6.4 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
-7.12 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
3.87 M | $ 1.03 | -2.36 % | $ 98.2 M | Canada |
 |
Tilray
TLRY
|
7.91 M | $ 5.04 | 1.1 % | $ 3.11 B | Canada |
 |
Evolus
EOLS
|
-42.3 M | $ 6.67 | -0.89 % | $ 430 M | USA |
 |
Sundial Growers
SNDL
|
-155 M | $ 1.41 | -1.06 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
171 M | $ 8.28 | -0.48 % | $ 443 M | USA |
 |
Veru
VERU
|
-30 M | $ 3.1 | 3.47 % | $ 45.4 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-77.2 M | - | - | $ 193 M | Canada |
 |
cbdMD
YCBD
|
-1.45 M | $ 0.69 | 0.89 % | $ 2.78 M | USA |
 |
Assertio Holdings
ASRT
|
-28.2 M | $ 23.5 | 0.09 % | $ 150 M | USA |
 |
ProPhase Labs
PRPH
|
-8.34 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-22.4 M | - | - | $ 1.42 B | USA |
 |
Bausch Health Companies
BHC
|
1.4 B | $ 5.01 | -0.89 % | $ 1.86 B | Canada |
 |
PetIQ
PETQ
|
61.9 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
-45.8 M | $ 6.59 | -0.9 % | $ 260 M | USA |
 |
Recro Pharma
REPH
|
-1 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-44.7 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
-5.28 M | $ 4.2 | -0.71 % | $ 210 M | USA |
 |
PLx Pharma
PLXP
|
-32.1 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
2.32 B | $ 16.36 | -0.7 % | $ 19.1 B | USA |
 |
Zomedica Corp.
ZOM
|
-17.6 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-23 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-659 K | $ 0.66 | 5.44 % | $ 23.7 M | USA |
 |
Tricida
TCDA
|
-140 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
148 K | $ 0.76 | 2.34 % | $ 3.26 M |  China |
 |
TherapeuticsMD
TXMD
|
-159 M | $ 2.29 | 4.18 % | $ 26.5 M | USA |